Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05998629 · ClinicalTrials.gov registry record · NA

Skin-interfaced Colorimetric Bifluidic Sweat Sensor Device for the Diagnosis of Cystic Fibrosis (CF)

A NA study of Cystic Fibrosis, sponsored by Milton S. Hershey Medical Center.

Recruiting
Registry status
NA
Development phase
30
Enrollment target
1
Study location

NCT05998629 is a NA study of Cystic Fibrosis that is actively recruiting participants, run by Milton S. Hershey Medical Center. The registered enrollment target is 30 participants, below the 179-participant average among 169 other Cystic Fibrosis trials with a reported enrollment target (83% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05998629, a NA study of Cystic Fibrosis, is actively recruiting participants, sponsored by Milton S. Hershey Medical Center.

RECRUITING
Registry status
NA
Development phase
30 participants
Enrollment target
1
Study location

Study Summary

Cystic fibrosis (CF) is a multisystem autosomal recessive inherited disease affecting approximately 75,000 individuals in USA. The sweat chloride (Cl) test remains the gold standard for diagnosis of CF but still has a number of limitations. The objectives of this study are: 1)To evaluate a skin-interfaced colorimetric bifluidic sweat device with two synchronous channels as a potential low-cost but potentially accurate test to diagnoses cystic fibrosis (CF) and 2) To evaluate measurements of sweat chloride (Cl) using this same system in comparison to the standard clinical laboratory procedures routinely performed in the Clinical Laboratory at Penn State Health Milton S. Hershey Medical Center (PSH-HMC), Hershey, PA for assessment of the diagnosis of CF. This is a single institution study performed solely at PSH-HMC. Study participants will include 1) adults 18 years of age or older capable of providing signed and dated informed consent, 2) subjects with an established known diagnosis of cystic fibrosis (CF) or healthy volunteers, and 3) able to understand and speak English language. Exclusion criteria include: 1) any medical condition or disorder known to potentially interfere with accurate measurements of sweat chloride and 2) inability to understand and speak the English language. Cystic Fibrosis (CF) subjects will be identified from the population of eligible patients receiving medical care at Penn State Health- Milton S. Hershey Medical Center (PSH-HMC). Healthy donor volunteers will be recruited from various members of the PSH-HMC CF clinical care team, members of the Division of Allergy, Pulmonary and Critical Care (both faculty and trainees) at PSH-HMC, and PSU-University Park research team. The total projected number of combined enrolled subjects is 30. This is a single day single time study that will require approximately 60 minutes of subject participation. Potential risks include a) side effects from pilocarpine iontophoresis sweat test collection (pain, s

Conditions Studied

Interventions

  • DEVICE a skin-interfaced colorimetric bifluidic sweat device with two synchronous channels
  • OTHER Standard of Care laboratory procedure for measurement of sweat

Study Locations (1)

Pennsylvania

  • Penn State Milton S. Hershey Medical Center - Hershey

Trial Details

FieldValue
Enrollment Target 30 participants
Start Date 2024-07-01
Est. Completion 2026-12-01
Phase NA

Sponsor

Milton S. Hershey Medical Center

396 total trials

What the Registry Record Tells You About NCT05998629

The ClinicalTrials.gov registry entry for NCT05998629 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 179-participant average among 169 other Cystic Fibrosis trials with a reported enrollment target (83% lower). The listed sponsor is Milton S. Hershey Medical Center, which has 396 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Cystic Fibrosis appearing as the primary indexed condition, and to 2 interventions - of which a skin-interfaced colorimetric bifluidic sweat device with two synchronous channels is the first listed.

NCT05998629 reports 1 study location spanning 1 distinct geographic area - top geographies include Pennsylvania.

Frequently Asked Questions

What is clinical trial NCT05998629 about?

NCT05998629 is a clinical study titled "Skin-interfaced Colorimetric Bifluidic Sweat Sensor Device for the Diagnosis of Cystic Fibrosis (CF)". Cystic fibrosis (CF) is a multisystem autosomal recessive inherited disease affecting approximately 75,000 individuals in USA. The sweat chloride (Cl) test remains the gold standard for diagnosis of CF but still has a number of limitations. The objectives of this study are: 1)To evaluate a skin-inte...

What is the current status of trial NCT05998629?

This trial is currently recruiting. It is a NA study. The enrollment target is 30 participants. The study started on 2024-07-01. Estimated completion is 2026-12-01.

What conditions does trial NCT05998629 study?

This clinical trial studies the following conditions: Cystic Fibrosis.

What interventions are being tested in trial NCT05998629?

The interventions under investigation include: a skin-interfaced colorimetric bifluidic sweat device with two synchronous channels (DEVICE), Standard of Care laboratory procedure for measurement of sweat (OTHER).

Who is sponsoring clinical trial NCT05998629?

This trial is sponsored by Milton S. Hershey Medical Center, which has 396 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05998629 being conducted?

This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Cystic Fibrosis

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.